Cerebral venous thrombosis (CVT) is an uncommon venous-type of stroke tends to affect younger
patients with somewhat different risk factors and much better outcome compared to arterial
strokes. Anti-coagulation is the standard of treatment for patients with (CVT) initially with
heparins followed by other oral blood thinners for several months. In this study, the
investigators are comparing warfarin with another well-known blood thinner, rivaroxaban,
which has a fixed once-daily dose with no need for monitoring in terms of clinical outcomes
and complications.